Ewa Robak

Articles in Scholarly Journals [Incomplete List]

  1. Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
    Mediators of Inflammation, vol. 2006, Article ID 17898, 7 pages, 2006
  2. Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus
    Mediators of Inflammation, vol. 13, no. 3, pp. 171–180, 2004
  3. Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients
    Mediators of Inflammation, vol. 12, no. 2, pp. 95–99, 2003
  4. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus
    Mediators of Inflammation, vol. 12, no. 5, pp. 293–298, 2003
  5. Lymphocytes Tγδ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity
    Mediators of Inflammation, vol. 10, no. 4, pp. 179–189, 2001
  6. Circulating TCR gammadelta cells in the patients with systemic lupus erythematosus
    Mediators of Inflammation, vol. 8, no. 6, pp. 305–312, 1999
  7. Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation
    Mediators of Inflammation, vol. 8, no. 2, pp. 93–100, 1999
  8. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
    Mediators of Inflammation, vol. 7, no. 5, pp. 347–353, 1998
  9. Tumour necrosis factor a (TNF-a), interleukin-6 (IL-6) and their soluble receptors (sTNF-a-Rp55 and slL-6R) serum levels in systemic lupus erythematodes
    Mediators of Inflammation, vol. 5, no. 6, pp. 435–441, 1996